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Abstract 
Tobacco smoke and air pollutants contain carcinogens, such as polycyclic aromatic 
hydrocarbons (PAHs) and tobacco specific nitrosamines (TSNA), that are substrates of 
metabolizing enzymes generating reactive metabolites that can bind to DNA. Variation in 
the activity of these enzymes may modify the extent to which these metabolites can interact 
with DNA. We compared the levels of bulky DNA adducts in blood leukocytes from 93 
volunteers living in Mexico City with the presence of 13 single nucleotide polymorphisms 
(SNPs) in genes related to PAH and TSNA metabolism (AhR rs2044853, CYP1A1 
rs1048943, CYP1A1 rs1048943, CYP1A1 rs1799814, EPHX1 rs1051740, EPHX1 
rs2234922, GSTM1 null, GSTT1 null and GSTP1 rs947894), DNA repair (XRCC1 rs25487, 
ERCC2 rs13181 and MGMT rs12917) and cell cycle (TP53 rs1042522). 32P-postlabeling 
analysis was used to quantify bulky DNA adduct formation. Genotyping was performed 
using PCR-RFLP. The mean levels of bulky DNA adducts were 8.51±3.66 adducts/108 
nucleotides (nt) in smokers and 8.38±3.59 adducts/108 nt in non-smokers, being the 
difference not statistically significant. Without taking into account the smoking status, 
GSTM1null individuals had a marginally significant lower adduct levels compared with 
GSTM1 volunteers (p=0.0433) and individuals heterozygous for MGMT Leu/Phe had a 
higher level of bulky adducts than those who were homozygous wild-type (p=0.0170). A 
multiple regression analysis model showed a significant association between the GSTM1 
(deletion) and MGMT rs12917 (Phe/Phe) haplotype and the formation of DNA adducts in 
smokers (R2=0.2401, p=0.0215). The presence of these variants conferred a greater risk for 
higher adduct levels in this Mexican population. 
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PAH, polycyclic aromatic hydrocarbon; SNP, single nucleotide polymorphism; mEH, 
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complementation group 2/ xeroderma pigmentosum D; XRCC1, X-ray repair cross 
complementation-1; MGMT, O6-methylguanine-DNA methyltransferase; nt, nucleotides. 
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1. Introduction 
Many polycyclic aromatic hydrocarbons (PAHs), aromatic amines and tobacco specific 
nitrosamines (TSNA), which are present in tobacco smoke, food and urban air pollution, 
have been classified as carcinogens by the International Agency for Research on Cancer [1] 
and the USA Environmental Protection Agency [2]. These compounds have little inherent 
biological activity, but their toxicity results from the formation of reactive metabolites in 
the cell and they constitute the major, but not exclusive, source of bulky DNA adducts. 
Cytochrome 450 (CYP) enzymes play an important role in the generation of these reactive 
intermediates in a process described as the metabolic activation of PAHs and TSNAs [3, 4]. 
Experimental evidence has shown that the CYP1 family is modulated by the aryl 
hydrocarbon receptor (AhR), a ligand-activated transcription factor [5]. Models suggest that 
CYP1A1 catalyzes the addition of an oxygen atom to lipophilic carcinogens, such as PAHs, 
thereby increasing their water solubility and producing simple epoxides. Microsomal 
epoxide hydrolase (mEH) converts epoxides to dihydrodiols, which can subsequently be 
conjugated with glutathione, catalysed by glutathione S-transferases (GSTs), primarily GST 
M1, T1 and P1[6]. Thus, soluble metabolites are readily eliminated from organisms. In 
each of these reactions, highly reactive intermediates are usually formed that can react with 
DNA and proteins to form covalently bound adducts. Additionally, tobacco and food 
nitrosamines generate electrophilic metabolites that alkylate DNA [7]. The metabolic 
activation of nitrosamines to form DNA adducts proceeds via α-hydroxylation (i.e., 
hydroxylation of the carbon adjacent to the N-nitroso group) by CYP enzymes. This α-
hydroxylation at the methyl carbon produces α-hydroxymethyl nitrosamines with 
spontaneous formaldehyde loss and pyridyloxobutyl diazohydroxide production, which 
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reacts with DNA, thereby forming stable alkyl adducts [8]. Among these adducts, the O6-
methylguanine (O6-meG) adduct is considered to be one of the most mutagenic DNA 
lesions, and its carcinogenic effects have been documented. Unrepaired O6-meG lesions 
have been associated with increased frequencies of chromosomal aberrations and sister 
chromatid exchanges [8, 9, 10]. 
Bulky DNA adducts represent a major and important class of DNA damage originating 
from cigarette smoke exposure and environmental pollution [11, 12]. DNA adducts are 
removed by different repair pathways, including base excision repair (BER), nucleotide 
excision repair (NER) and direct reversal repair (DRR) [11]. MGMT plays an important 
role in removing primarily the O6-alkylguanines by DRR. A Leu to Phe change at position 
84 in the MGMT protein alters the enzyme substrate affinity [8, 13] and has been 
associated with increased lung cancer risk, which is greater in female smokers [14]. 
Similarly, polymorphisms in genes related to PAH and TSNA metabolism, including AhR, 
CYP1A1, EPHX, GSTM1, GSTT1 and GSTP1 and allelic variants in DNA repair enzymes 
genes (i.e., XRCC1, ERCC2 and MGMT; Table 1), have been described to contribute to the 
risk for developing lung cancer, suboptimal repair and PAH and TSNA sensitivity [8, 13, 
15]. 
PAH- and TSNA-DNA adducts in leukocytes are considered biomarkers of exposure to 
these carcinogens and are therefore cancer-risk indicators [9, 28]. 32P-Postlabeling is a 
sensitive assay to detect DNA adduct formation and is broadly applicable for a variety of 
adducts [29]. In the present study we investigated the association between the levels of 
bulky DNA adducts (measured by 32P-postlabeling) in blood leukocytes from healthy 
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smokers and non-smokers and the allelic risk variants of genes involved in cigarette smoke 
carcinogen activation, detoxification and DNA repair in a group of volunteers living in 
Mexico City.  
 
2. Materials and Methods 
2.1.Subjects and DNA isolation 
This study included healthy, non-related participants living in Mexico City who donated 
blood at the “20 de Noviembre” Hospital in Mexico City from October 2001 to November 
2004. The study protocol was approved by the Ethics Committee of the Instituto de 
Investigaciones Biomédicas, Universidad Nacional Autónoma de México, and the “20 de 
Noviembre” Hospital gave permission to use the buffy coat cells of blood bank samples as 
a source of DNA. After giving their informed consent, the smoker and non-smoker 
participants were asked about their overall health status and smoking habits. Smokers with 
tobacco indices lower than 0.05 or with incomplete data regarding their smoking habits 
(i.e., the number of cigarettes per day and/or years of smoking) were excluded. For the final 
analysis, 94 subjects were randomly selected and consisted of 43 smokers and 51 non-
smokers. Buffy coat cells were obtained from blood samples and DNA was isolated using a 
standard phenol-chloroform extraction protocol [30], aliquoted and frozen at −20°C until 
analysis. The integrity and purity of DNA (0.8 % agarose gel electrophoresis and A260/280 
index, respectively) were established for all samples before the 32P-postlabeling assay was 
initiated in January, 2010. 
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2.2. 32P-postlabeling 
Analysis by 32P-postlabeling was performed according to the previously described 
standardized procedure [29]. Briefly, DNA samples (4 µg) were digested overnight using a 
mixture of micrococcal nuclease and spleen phosphodiesterase at 37ºC. Nuclease P1 
digestion was used for adduct enrichment. The labeled DNA adducts were resolved by 
multi-directional thin-layer chromatography (TLC) on 10 × 20 cm PEI-cellulose plates 
(Machery-Nagel, Germany). The solvent systems used for TLC were as follows: D1: 1 M 
sodium phosphate, pH 6.0; D3: 4 M lithium formate, 7 M urea, pH 3.5; and D4: 0.8 M 
lithium chloride, 0.5 M Tris, 8.5 M urea, pH 8.0. After chromatography, TLC sheets were 
scanned using a Packard Instant Imager (Dowers Grove, IL, USA), and the DNA adduct 
levels (RAL; relative adduct labeling) were calculated from the adduct cpm, the specific 
activity of the [γ-32P]ATP and the amount of DNA (pmol of DNA-P) used. All samples 
were analyzed in triplicate on different days. An external benzo[a]pyrene diol-epoxide-
(BPDE)-modified DNA standard was used as a positive control [31]. DNA adduct levels 
were measured in the diagonal radioactive zone (DRZ) area of the TLC plates. The method 
provides a summary measure of a complex mixture of adducts present in the postlabeling 
chromatograms resistant to P1 digestion [32]. The results were expressed as DNA 
adducts/108 nucleotides (nt).  
 
2.3.Genotyping 
The polymerase chain reaction (PCR), restriction fragment length polymorphism (RFLP) 
and TaqMan allelic discrimination assays were performed for genotyping as previously 
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described by Pérez Morales and coworkers [33]. The results were expressed as DNA 
adducts/108 nucleotides (nt) 
 
2.4.Statistical analysis 
Age, cigarettes smoked per day, body mass index (BMI) and bulky DNA adduct levels in 
leukocytes from smokers and non-smokers were compared by bivariate analysis using the t-
test or Wilcoxon signed rank test after testing for normal distribution. The levels of adducts 
were transformed to Ln for statistical analysis. To explore the relationship between bulky 
DNA adduct levels and risk polymorphisms, the different allelic variants were grouped by 
genotypes and scored as follows: 0 (wild type homozygous); 1(heterozygous, one variant 
allele) and 2 (mutant homozygous). For GSTM1 and GSTT1, the presence of the allele was 
scored 0, and the null genotype was scored 2 because the presence of GSTM1 or GSTT1 in 
the homozygous or heterozygous condition has not been associated with increased adduct 
levels [21, 34]. In either case, to evaluate the possible association between adduct levels 
and each of the polymorphisms, t-test, one way ANOVA or Kruskall-Wallis tests were used 
accordingly. We controlled for multiple testing by Bonferroni correction using a 
conservative approach: a priori, we performed the correction for the effective number of 
independent tests by correlated SNPs, using a principal components analysis [35]. The 
threshold for array-wide statistical significance was established as p<0.025. Separate 
multivariate models were undertaken for smoker and non-smoker volunteers, these models 
included selected variables confirmed by the significant association observed in the 
bivariate analysis including only those that were significant or marginally significant. 
Finally, the quality of each final model was assessed by testing the statistical assumptions 
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by linear regression. A distribution of residuals was constructed to evaluate the final 
multivariate linear regression models. We assessed whether there were any individually 
influential outliers by residuals plots and Breusch-Pagan/Cook-Weisberg test for 
heteroscedasticity statistics. A p<0.05 was considered statistically significant to include the 
variables into the final model. All of the statistical analyses were performed using STATA 
SE.10 (Stata Corporation, College Station, TX) and SigmaPlot 10.0 (Systat Software Inc, 
San Jose, CA).  
All genotypes were in Hardy-Weinberg equilibrium. GSTM1 and GSTT1 were not analyzed 
for Hardy-Weinberg equilibrium because the analytical method used did not allow for the 
discrimination between heterozygous and homozygous-positive genotypes [33]. 
3. Results 
The bulky adduct levels were analyzed taking into consideration smoking status, age, 
gender, and BMI (Table 2). Outliers were excluded by principal component analysis. The 
mean levels of adducts were 8.51±3.66 adducts/108 nucleotides (nt) in smokers (n=42) and 
8.38±3.59 adducts/108 nt in non-smokers (n=51). The data were transformed for statistical 
analysis; the mean Ln levels of the adducts were 2.05±0.43 adducts/108 and 2.04±0.41 
adducts/108 nt in smokers and non-smokers, respectively, which were not significantly 
different. On average, smokers had approximately 1.5% more adducts than non-smokers, 
probably because 88% of the smokers were "low current smokers" (i.e., <10 cigarettes per 
day). In addition, no significant adduct level differences were observed with respect to 
gender and BMI.  
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Thus, the relationship between the bulky DNA adduct levels and the allelic variants 
were initially analyzed without taking into account the smoking status (Table 3). 
Individuals with GSTM1null genotype had a marginally significant lower adduct levels 
compared with those with GSTM1 genotype (p=0.0433). Moreover, those heterozygous for 
MGMT Leu/Phe had a higher level of bulky adducts (2.240 ±0.448 adducts/108 nt) than 
those who were homozygous wild-type (1.963±0.364 adducts/108 nt) (p=0.0170). 
If smoking status was taken into consideration, smokers with XRCC1 Arg/Gln, 
ERCC2 Lys/Gln or MGMT84 Leu/Phe genotypes showed higher levels of bulky adducts 
(2.24±0.39 adducts/108 nt, p=0.023; 2.27±0.51, p=0.16 and 2.240±0.448 adducts/108 nt, 
p=0.256, respectively) than those who were homozygous wild-type. Between non-smokers, 
only those with AhR Arg/Lys had lower levels of bulky adduct (p=0.045) compared with 
homozygous wild-type (data not shown). 
We performed a regression analysis model to associate the adduct levels versus the allelic 
variants through interactions with different genetic polymorphisms and their possible 
combinations in 38 smokers and 43 non-smokers (Table 4). Significant predictor 
haplotypes were found among non-smokers: AhR rs2066853 (Arg/Lys) was positively and 
significantly associated with adduct formation (β=0.327; p=0.006), and GSTM1null 
(deletion) and MGMT84 rs12917 (Phe/Phe) were negatively associated with bulky DNA 
adduct formation (β=-0.641; p=0.035). These haplotypes explain 10 and almost 7% of the 
variability, respectively. Among smokers, the interaction between GSTM1null (deletion) 
and MGMT84 rs12917 (Phe/Phe) was positively and significantly associated with adduct 
formation (β=1.055; p=0.015), explaining 14% of the variability. To validate the 
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multivariate linear regression model, we examined the residuals. Across all of the predicted 
bulky adducts, the level of the distribution of the residuals was normal and homoscedastic 
(Chi2 (1)=0.45; Probability > Chi2=0.5031). Thus, the AhR rs2066853 (Arg/Lys), 
GSTM1null (deletion) and MGMT84 rs12917 (Phe/Phe) haplotype represents our predictive 
model for the higher risk of bulky adduct formation in this Mexican population. 
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4. Discussion 
Molecular epidemiology studies have shown significant interindividual variations in 
the levels of DNA adduct formation [32]. These variations have been attributed to the 
differences in the metabolism and elimination of xenobiotics and DNA repair processes, 
which could be explained by the presence of genetic polymorphisms in a proportion of the 
genes encoding the enzymes that participate in these processes. Moreover, several 
epidemiological studies have shown that single nucleotide polymorphisms (SNPs) are 
associated with differential biological activities or increased cancer risk (Table 1). We 
investigated the relationship between the bulky DNA adduct levels detected by 32P-
postlabeling assay in leukocytes from healthy smokers and non-smokers and 13 SNPs 
involved in PAH and TSNA metabolism (AhR (rs2066853), CYP1A1 (rs4646903), 
CYP1A1 (rs1048943), CYP1A1 (rs1799814), EPHX1 (rs1051740), EPHX1 (rs2234922), 
GSTM1, GSTT1 and GSTP1 (rs947894)), DNA repair (XRCC1 (rs25487), ERCC2 (rs1318) 
and MGMT84 (rs12917)) and the cell cycle (TP53 (rs1042522)). 
No association was found between age and adduct levels (Table 2). Positive correlations 
between the smoking-related adduct levels and age have been reported only in persons 
above the age of 60, presumably reflecting environmental, lifestyle, DNA repair and 
genetic factors [36, 37]. No differences were found between bulky adduct levels in smokers 
and non-smokers, probably because 88% (38 out of 42) of the smokers were “low current” 
smokers according to the number of cigarettes smoked per day (i.e., <10 cigarettes/day), 
and no correlations were found between PAH-related DNA adduct formation and the low 
current smoking status in similar studies on Caucasians [38]. Alternatively, diet is also a 
potential source for DNA adduct formation in blood [38, 39, 40]. The levels of adducts can 
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be altered as a function of the quantity of PAHs ingested during consumption of charcoal-
broiled beef [41]; however, we have no information on the diet composition of these 
volunteers to allow similar analysis. 
Individuals with GSTM1null genotype had a marginally significantly lower adduct levels 
compared with those who were GSTM1 positive (p=0.0433; Table 3). Higher PAH-DNA 
adduct levels have been associated to GSTM1null genotype in Caucasians; in contrast, no 
differences were found in African-American and Latino populations with respect to the 
GSTM1 status [42]. There are a great number of studies on GSTM1null individuals which 
report different relations of this null genotype and DNA adduct levels quantified by 
different techniques [42, 43, 44]. A limitation of our study was the relatively small number 
of GSTM1null subjects. To clarify the participation of GSTM1 null genotype in the 
Mexican population a larger sample needs to be analyzed in future studies. 
In human lymphocytes, the MGMT rs12917 (Leu84Phe) polymorphism results in 
suboptimal repair of genetic damage and increased NNK (4-[methylnitrosamino]-1-[3-
pyridyl]-1-butanone) sensitivity, as detected by the formation of in vitro chromosomal 
aberrations [8]. Moreover, the MGMT rs12917 (Leu84Phe) polymorphism and suboptimal 
repair were also associated with increased mutation frequency in the lymphocytes of 
smokers compared with smokers carrying the wild-type allele [10, 44]. Accordingly, we 
observed significantly higher adduct levels in the individuals heterozygous for MGMT 
Leu/Phe than in the homozygous wild-type individuals (p=0.0170; Table 3). These results 
are interesting because the typical adducts which are repaired by MGMT enzyme involve 
alkyl and POB adducts derived from NNK metabolisms [45] that are generally detected by 
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HPLC-immunoassay or by enrichment with immunoaffinity columns prior to 32P-
postlabeling [46, 47], procedures that were not used in this study. 
The conditions used in this 32P-postlabeling assay allows for quantification of a wide range 
of bulky DNA adducts [48, 49, 50] which are revealed in the diagonal radioactivity zone 
(DRZ) on 2-dimensional thin-layer chromatograms generated by resolution of the labeled 
digests. Complex mixture like tobacco smoke and air pollution contain over 4000 
compounds and can potentially generate numerous unidentified DNA adducts in the tissues 
[51]. Using urea based solvents, detection in the DRZ of intrastrand DNA-DNA cross links 
formed by treatment of DNA with hydroxyl radicals has been reported [52, 53] suggesting 
that some of the DNA adducts detectable in the DRZ in our assays may also represent DNA 
cross-links at the O6 position of guanine generated by butadiene, catechols and aldehydes 
presents in tobacco smoke [54, 55]. The human MGMT enzyme could participate in the 
repair of such products [56]. 
Another hypothesis on the relationship of MGMT and bulky DNA adduct formation is that 
MGMT might bind directly to AhR and prevent AhR association with its co-activators, 
which down-regulates the AhR-mediated transcription of the genes implicated in the 
activation of the xenobiotics. It was suggested that MGMT could serve as a sensor of DNA 
exposure to alkylating agents (which are, in our case, concomitant to the typical bulky 
xenobiotic AhR ligands occurring in air and smoke pollution) thus controlling nuclear 
receptors implied in cell proliferation according to the extent of DNA damage [57, 58, 59]. 
As yet, no molecular interaction between AhR and MGMT has been documented; however, 
the fact that MGMT contains the consensus LxxLL motif of transcriptional co-activators 
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[60, 61] fully recognized by AhR [62] makes this hypothesis plausible. Indeed, MGMT was 
shown to bind to estrogen receptor (ER) through its LxxLL motif-containing peptide 
domain exposed upon suicide DNA repair trans-alkylation of MGMT [63]. This binding 
modulates ER association with ER co-activators to negatively regulate ER-mediated 
transcription [64]. Based on the data obtained in this study on the relationship of MGMT 
polymorphism and bulky DNA adduct formation, the alkylated Leu84Phe allelic variant 
MGMT is suggested to have decreased affinity for AhR binding and to exert diminished 
AhR sequestering activity compared to the alkylated form of wild-type MGMT. As a 
consequence, more AhR would be available for PAH binding in MGMT Leu84Phe cells 
resulting in effective transcription activation of, e.g., phase I enzymes CYP1A1, CYP1A2 
that activate PAH-DNA binding. This idea is supported by the notion that Leu84Phe 
substitution is adjacent to His85 residue involved Zn (II) binding in MGMT [59] and is 
separated by 15 aa from the LxxLL motif.  
The individual genetic risk from exposure to tobacco carcinogens is governed by a 
combination of genetic polymorphisms in different xenobiotic-metabolizing genes. Our 
model suggests that individuals with the AhR (rs2066853), GSTM1null (deletion) and the 
MGMT 84 (rs12917) haplotypes exhibit an increased risk for the formation of bulky DNA 
adducts in leukocytes. This model explains 24% of the DNA adducts in leukocytes, while 
the 76% of the variability remains unexplained (Table 4). The strength of this model is that 
we selected only risk haplotypes associated with the higher adduct levels. It is also 
important to consider that we used a simple regression model to account for interacting 
gene effects; however, these observations require confirmation from in a larger study. This 
model assumes that the three genes have a meaningful biological relationship that is linear 
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and continuous, and the risk may be enhanced by exposure to environmental PAHs, or 
tobacco-smoke carcinogens.  
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Table 1. Alellic variants in genes associated with increased health risk due to exposure to 
PAHs and TSNAs and their biological effect. 
Gen SNP Biological Effect References 
AhR (rs2066853) Arg554Lis Expression of CYP1 family [16] 
CYP1A1 (rs4646903) 
CYP1A1 (rs1048943) 
CYP1A1 (rs1799814) 
T3801C 
Ile462Val 
Thr461Asn 
Higher CYP1A1 expression 
Higher CYP1A1 activity 
Lower CYP1A1 activity 
[17] 
[18] 
[19] 
EPHX1 (rs1051740) 
EPHX1 (rs2234922) 
Tyr113His 
His139Arg 
50% activity decrease 
25% activity increase 
[20] 
GSTM1 (deletion) 
GSTT1 (deletion) 
GSTP1 (rs947894) 
null 
null 
Ile105Val 
Higher DNA adduct levels 
[21] 
[22] 
[23] 
XRCC1 (rs25487) 
ERCC2 (rs1318) 
MGMT84 (rs12917) 
Arg399Gln 
Lys751Gln 
Leu84Phe 
Decrease in lung cancer risk 
Higher DNA adduct levels 
Suboptimal repair and human 
sensitivity to TSNA 
[24] 
[25], [26] 
[8], [13] 
TP53 (rs1042522) Arg72Pro Increases the risk of cancer, COPD 
and bronchial diseases [27] 
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Table 2. Age, cigarettes smoked per day, BMI and bulky DNA adduct levels in leukocytes from 
smokers and non-smokers. 
 N Non smokers 
mean ±S.D. 
N Smokers 
mean ±S.D. 
P value 
Age [years] 
Female  
Male 
51 
26 
25 
36.92±10.92 
38.96±10.97 
34.80±9.971 
42 
20 
22 
36.37±10.85 
34.75±9.296 
37.78±12.08 
NS 
Number of cigarettes smoked per day 
Female 
Male 
51 
26 
25 
0 
0 
0 
42 
20 
22 
5.99±5.95 
5.92±4.92 
6.25±6.93 
< 0.0001a 
< 0.0001a 
< 0.0001a 
Ln (adducts/ 108nt) 
Female 
Male  
51 
26 
25 
2.04±0.41 
2.01±0.42 
2.07±0.39 
42 
20 
22 
2.05±0.43 
2.12±0.39 
1.99±0.46 
NS 
BMI 
Female 
50b 
26 
26.98±4.70 
27.95±4.79 
42 
20 
26.2±3.28 
26.65±2.97 
NS 
25 
 
Male 24b 25.93±4.46 22 25.80±3.56 
 
Body mass index (BMI)  
a Wilcoxon signed rank test 
b One sample without BMI 
NS No significant differences in each group (p>0.05) using Student’s t-test. 
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Table 3. Mean Ln of adducts /108 nt and Median of adducts/108 nt associated with the 
different allelic variants. 
Genotypes Nc 
Ln of adducts /108 nt Adducts /108 nt 
P value* 
Mean (S.D) Median (IQR) 
AhR (rs2066853) 
Arg/Arg  
Arg/Lys 
Lys/Lys 
 
52 
29 
0 
 
2.056 (0.383) 
1.931 (0.462) 
- 
 
7.69 (3.98) 
5.98 (3.86) 
- 
0.1808a 
CYP1A1 (rs1048943) 
Ile/Ile 
Ile/Val 
Val/Val 
 
17 
55 
21 
 
1.917 (0.413) 
2.061 (0.387) 
2.116 (0.479) 
 
6.73 (4.83) 
7.55 (4.69) 
8.48 (7.12) 
0.3197b 
CYP1A1 (rs4646903) 
T/T 
T/C 
 
24 
49 
 
2.038 (0.475) 
2.044(0.339) 
 
7.26 (6.56) 
7.83 (3.60) 
0.9757b 
27 
 
C/C 20 2.065 (0.518) 7.58 (7.76) 
CYP1A1 (rs1799814) 
Thr/Thr 
Thr/Asn 
Asn/Asn 
 
78 
13 
2 
 
2.063 (0.419) 
1.947 (0.405) 
2.076 (0.435) 
 
7.76 (4.79) 
7.14 (3.82) 
8.36 (4.99) 
0.6485c 
EPHX1 (rs1051740) 
Tyr/Tyr 
Tyr/His 
His/His 
 
23 
41 
29 
 
2.146 (0.447) 
2.082 (0.411) 
1.919 (0.374) 
 
9.19 (6.14) 
7.83 (4.75) 
6.39 (4.22) 
0.1133b 
EPHX1 (rs2234922) 
His/His 
His/Arg 
Arg/Arg 
 
70 
23 
0 
 
2.021 (0.419) 
2.126 (0.397) 
- 
 
7.38 (4.79) 
8.48 (4.86) 
- 
0.2973a 
GSTM1 (deletion) 
Positive 
 
63 
 
2.106 (0.411) 
 
8.50 (4.75) 
0.0433a 
28 
 
Null 30 1.922 (0.401) 6.54 (4.66) 
GSTT1 (deletion) 
Positive 
Null 
 
74 
19 
 
2.025 (0.428) 
2.133 (0.354) 
 
7.43 (4.89) 
8.75 (4.5) 
0.3143a 
GSTP1 (rs947894) 
Val/Val 
Ile/Val 
Ile/Ile 
 
19 
51 
23 
 
2.083 (0.445) 
2.068 (0.411) 
1.971 (0.406) 
 
7.51 (5.82) 
8.10 (4.70) 
6.22 (5.24) 
0.5935b 
XRCC1 (rs25487) 
Arg/Arg 
Arg/Gln 
Gln/Gln 
 
53 
36 
2 
 
1.992 (0.430) 
2.123 (0.394) 
1.816 (0.258) 
 
6.59 (4.26) 
8.59 (5.38) 
6.25 (2.26) 
0.2091c 
ERCC2 (rs1318) 
Lys/Lys 
Lys/Gln 
 
59 
27 
 
2.060 (0.393) 
2.028 (0.457) 
 
7.83 (4.75) 
7.55 (5.21) 
0.9259b 
29 
 
Gln/Gln 7 2.015 (0.483) 5.98 (5.73) 
MGMT (rs12917) 
Leu/Leu 
Leu/Phe 
Phe/Phe 
 
54 
26 
13 
 
1.963 (0.364) 
2.240 (0.448) 
2.012 (0.447) 
 
7.26 (3.82) 
10.16 (6.54) 
7.37 (4.78) 
0.0170b 
TP53 (rs1042522) 
Arg/Arg 
Arg/Pro 
Pro/Pro 
 
47 
31 
15 
 
2.074 (0.422) 
1.984 (0.428) 
2.095 (0.371) 
 
7.69 (4.77) 
7.38 (4.84) 
8.75 (5.01) 
0.4756b 
a
 t-test with equal variances for two groups 
b One way ANOVA test with equal variances 
c
 Kruscall-Wallis test (non parametric) 
d
 Numbers do not add up to expected totals because of missing genotyping data.  
* p value < 0.025 was considered significant after Bonferroni correction using correlated SNPs. 
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Table 4. Multiple linear regression analysis of predictors for bulky DNA adducts. 
Covariates Non-smokers (N=43)e Smokers (N=38)e 
 Multivariate r2  
variability 
explained d 
Multivariate r2  
variability 
explained d 
β 
a
 
Coefficient 
P b 
value 
Prob > F c β a 
Coefficient 
P b 
value 
Prob > F c 
AhR (Arg/Lys) 0.327 0.006 
0.0365 
10.67% -0.0123 0.931 
0.0215 
0.64% 
XRCC1 (Arg/Gln) 0.066 0.601 0.3% -0.204 0.140 1.34% 
ERCC2/XPD (Lys/Gln) -0.169 0.153 2.52% 0.037 0.822 0.012% 
Interaction of GSTM1 null 
with MGMT (Phe/Phe) 
-0.641 0.035 6.94% 1.055 0.015 14.55% 
r2 18.17% 24.01% 
a
 β Regression coefficient: the unit change of dependent variable caused by 1 unit change of independent variable. For genotype 
covariates, β is the difference of the mean of each genotype coded as 0 or 1. 
